Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Income from Continuing Operations of 111204000.0 for Q1 2026, down 54.48% year-over-year from 244308732.83 in Q1 2025, and down 1.04% quarter-over-quarter from 110059000.0 in Q4 2025.
Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Income from Continuing Operations for 10 consecutive years, with 111204000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 54.48% year-over-year to 111204000.0; the TTM figure through Mar 2026 stood at 382528000.0 (down 41.15% YoY), while the FY2025 annual figure was 1080622000.0, down 126.83% from the prior year.
- Income from Continuing Operations slipped to 111204000.0 in Q1 2026 per COGT's latest filing, from 110059000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 35907000.0 in Q1 2022 and bottomed at 111204000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 66121176.47 across 5 years, with a median of 62752000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 243.33% — and 2023, when it soared 36.61%.
- Cogent Biosciences' Income from Continuing Operations stood at 39984000.0 in 2022, then slumped by 47.54% to 58994000.0 in 2023, then fell by 1.64% to 59959000.0 in 2024, then sank by 83.56% to 110059000.0 in 2025, then fell by 1.04% to 111204000.0 in 2026.
- Business Quant data shows COGT's Income from Continuing Operations at 111204000.0 in Q1 2026, 110059000.0 in Q4 2025, and 85218000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -101.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -101.72 Mn |
| Mar 31, 2026 | -111.20 Mn |
| Dec 31, 2025 | -110.06 Mn |
| Sep 30, 2025 | -85.22 Mn |
| Jun 30, 2025 | -76.05 Mn |
| Mar 31, 2025 | -71.99 Mn |
| Dec 31, 2024 | -59.96 Mn |
| Sep 30, 2024 | -74.33 Mn |
| Jun 30, 2024 | -64.73 Mn |
| Mar 31, 2024 | -62.75 Mn |
| Dec 31, 2023 | -58.99 Mn |
| Sep 30, 2023 | -59.83 Mn |
| Jun 30, 2023 | -47.30 Mn |
| Mar 31, 2023 | -43.12 Mn |
| Dec 31, 2022 | -39.98 Mn |
| Sep 30, 2022 | -48.03 Mn |
| Jun 30, 2022 | -74.62 Mn |
| Mar 31, 2022 | -35.91 Mn |
| Dec 31, 2021 | -26.82 Mn |
| Sep 30, 2021 | -20.17 Mn |